438 related articles for article (PubMed ID: 19454302)
1. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
Pandi-Perumal SR; Moscovitch A; Srinivasan V; Spence DW; Cardinali DP; Brown GM
Prog Neurobiol; 2009 Aug; 88(4):264-71. PubMed ID: 19454302
[TBL] [Abstract][Full Text] [Related]
2. Circadian rhythm in bipolar disorder: A review of the literature.
Takaesu Y
Psychiatry Clin Neurosci; 2018 Sep; 72(9):673-682. PubMed ID: 29869403
[TBL] [Abstract][Full Text] [Related]
3. Circadian rhythms, melatonin and depression.
Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of depression: role of sleep and the melatonergic system.
Srinivasan V; Pandi-Perumal SR; Trakht I; Spence DW; Hardeland R; Poeggeler B; Cardinali DP
Psychiatry Res; 2009 Feb; 165(3):201-14. PubMed ID: 19181389
[TBL] [Abstract][Full Text] [Related]
5. Addressing circadian rhythm disturbances in depressed patients.
Lam RW
J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
[TBL] [Abstract][Full Text] [Related]
6. Role of melatonin in mood disorders and the antidepressant effects of agomelatine.
Srinivasan V; De Berardis D; Shillcutt SD; Brzezinski A
Expert Opin Investig Drugs; 2012 Oct; 21(10):1503-22. PubMed ID: 22876742
[TBL] [Abstract][Full Text] [Related]
7. [Depression as chronobiological illness].
Kálmán J; Kálmán S
Neuropsychopharmacol Hung; 2009 Jun; 11(2):69-81. PubMed ID: 19827314
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine in depressive disorders: its novel mechanisms of action.
Srinivasan V; Zakaria R; Othman Z; Lauterbach EC; Acuña-Castroviejo D
J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
[TBL] [Abstract][Full Text] [Related]
9. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
Mairesse J; Silletti V; Laloux C; Zuena AR; Giovine A; Consolazione M; van Camp G; Malagodi M; Gaetani S; Cianci S; Catalani A; Mennuni G; Mazzetta A; van Reeth O; Gabriel C; Mocaër E; Nicoletti F; Morley-Fletcher S; Maccari S
Int J Neuropsychopharmacol; 2013 Mar; 16(2):323-38. PubMed ID: 22310059
[TBL] [Abstract][Full Text] [Related]
10. Melatonergic drugs in clinical practice.
Hardeland R; Poeggeler B; Srinivasan V; Trakht I; Pandi-Perumal SR; Cardinali DP
Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
12. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
Quera-Salva MA; Lemoine P; Guilleminault C
Hum Psychopharmacol; 2010 Apr; 25(3):222-9. PubMed ID: 20373473
[TBL] [Abstract][Full Text] [Related]
13. Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
Jakovljević M
Psychiatr Danub; 2011 Mar; 23(1):2-9. PubMed ID: 21448091
[TBL] [Abstract][Full Text] [Related]
14. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
De Berardis D; Marini S; Fornaro M; Srinivasan V; Iasevoli F; Tomasetti C; Valchera A; Perna G; Quera-Salva MA; Martinotti G; di Giannantonio M
Int J Mol Sci; 2013 Jun; 14(6):12458-83. PubMed ID: 23765220
[TBL] [Abstract][Full Text] [Related]
15. Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis.
McGowan NM; Kim DS; de Andres Crespo M; Bisdounis L; Kyle SD; Saunders KEA
CNS Drugs; 2022 Apr; 36(4):345-363. PubMed ID: 35305257
[TBL] [Abstract][Full Text] [Related]
16. Melatonin and melatonergic drugs on sleep: possible mechanisms of action.
Srinivasan V; Pandi-Perumal SR; Trahkt I; Spence DW; Poeggeler B; Hardeland R; Cardinali DP
Int J Neurosci; 2009; 119(6):821-46. PubMed ID: 19326288
[TBL] [Abstract][Full Text] [Related]
17. The preclinical discovery and development of agomelatine for the treatment of depression.
Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
Expert Opin Drug Discov; 2020 Oct; 15(10):1121-1132. PubMed ID: 32568567
[TBL] [Abstract][Full Text] [Related]
18. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
19. The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms.
Perugi G; Quaranta G; Bucci N
Expert Opin Investig Drugs; 2015 May; 24(5):705-13. PubMed ID: 25727766
[TBL] [Abstract][Full Text] [Related]
20. Melatonin in mood disorders.
Srinivasan V; Smits M; Spence W; Lowe AD; Kayumov L; Pandi-Perumal SR; Parry B; Cardinali DP
World J Biol Psychiatry; 2006; 7(3):138-51. PubMed ID: 16861139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
